Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells.

Literature DB >> 11044364

Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells.

E Aurlien¹, R H Larsen, G Kvalheim, O S Bruland.

Abstract

The ability of an alpha-emitter conjugated to a chimaeric anti-CD20 monoclonal antibody to kill selectively human B-lymphoma cells in vitro is reported. Two B-lymphoma cell lines RAEL and K422, and normal haematopoietic progenitor cells from human bone marrow aspirates were incubated with(211)At-rituximab (Rituxan(R) or MabTheratrade mark) and plated in clonogenic assays for survival analyses. Following 1 h incubation with(211)At-rituximab, in concentrations which gave an initial activity of 50 kBq ml(-1), a high tumour cell to normal bone marrow cell toxicity ratio was obtained; 4.1 to 1.0 log cell kill. Biodistribution studies of(211)At-rituximab in Balb/c mice showed similar stability as that of the iodinated analogue. The data indicate that testing of(211)At-rituximab in human patients is warranted. Copyright 2000 Cancer Research Campaign.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2000 PMID： 11044364 PMCID： PMC2408791 DOI： 10.1054/bjoc.2000.1453

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

21 in total

1. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.

Authors: T Lindmo; E Boven; F Cuttitta; J Fedorko; P A Bunn
Journal: J Immunol Methods Date: 1984-08-03 Impact factor: 2.303

Review 2. Treatment of non-Hodgkin's lymphoma.

Authors: J O Armitage
Journal: N Engl J Med Date: 1993-04-08 Impact factor: 91.245

Review 3. Astatine-211: its possible applications in cancer therapy.

Authors: I Brown
Journal: Int J Rad Appl Instrum A Date: 1986

4. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.

Authors: G Sgouros; A M Ballangrud; J G Jurcic; M R McDevitt; J L Humm; Y E Erdi; B M Mehta; R D Finn; S M Larson; D A Scheinberg
Journal: J Nucl Med Date: 1999-11 Impact factor: 10.057

5. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.

Authors: R H Larsen; K M Murud; G Akabani; P Hoff; O S Bruland; M R Zalutsky
Journal: J Nucl Med Date: 1999-07 Impact factor: 10.057

6. A new human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t (14;18) and t(4;11) chromosomal translocations.

Authors: M J Dyer; P Fischer; E Nacheva; W Labastide; A Karpas
Journal: Blood Date: 1990-02-01 Impact factor: 22.113

7. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

Authors: M E Reff; K Carner; K S Chambers; P C Chinn; J E Leonard; R Raab; R A Newman; N Hanna; D R Anderson
Journal: Blood Date: 1994-01-15 Impact factor: 22.113

8. Efficacy of astatine-211-labeled monoclonal antibody in treatment of murine T-cell lymphoma.

Authors: A Harrison; L Royle
Journal: NCI Monogr Date: 1987

9. Elimination of B-lymphoma cells from human bone marrow: model experiments using monodisperse magnetic particles coated with primary monoclonal antibodies.

Authors: G Kvalheim; O Fodstad; A Pihl; K Nustad; A Pharo; J Ugelstad; S Funderud
Journal: Cancer Res Date: 1987-02-01 Impact factor: 12.701

10. An in vitro colony assay for human tumours grown in immune-suppressed mice and treated in vivo with cytotoxic agents.

Authors: V D Courtenay; J Mills
Journal: Br J Cancer Date: 1978-02 Impact factor: 7.640

11 in total

1. Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention.

Authors: D Scott Wilbur; Ming-Kuan Chyan; Donald K Hamlin; Holly Nguyen; Robert L Vessella
Journal: Bioconjug Chem Date: 2011-05-05 Impact factor: 4.774

2. In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage.

Authors: Katia Vandenbulcke; Filip De Vos; Fritz Offner; Jan Philippé; Christos Apostolidis; Roger Molinet; Tuomo K Nikula; Klaus Bacher; Virginie de Gelder; Anne Vral; Christophe Lahorte; Hubert Thierens; Rudi A Dierckx; Guido Slegers
Journal: Eur J Nucl Med Mol Imaging Date: 2003-07-03 Impact factor: 9.236

Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells.

1. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.

Review 2. Treatment of non-Hodgkin's lymphoma.

Review 3. Astatine-211: its possible applications in cancer therapy.

4. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.

5. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.

6. A new human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t (14;18) and t(4;11) chromosomal translocations.

7. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

8. Efficacy of astatine-211-labeled monoclonal antibody in treatment of murine T-cell lymphoma.

9. Elimination of B-lymphoma cells from human bone marrow: model experiments using monodisperse magnetic particles coated with primary monoclonal antibodies.

10. An in vitro colony assay for human tumours grown in immune-suppressed mice and treated in vivo with cytotoxic agents.

1. Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention.

2. In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage.

Review 3. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

Review 4. Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.

Review 5. Cancer radioimmunotherapy with alpha-emitting nuclides.

6. Astatine Radiopharmaceuticals: Prospects and Problems.

7. New strategies in radioimmunotherapy for lymphoma.

Review 8. The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma.

Review 9. Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.

10. Anti-CD20 Immunoglobulin G Radiolabeling with a 99mTc-Tricarbonyl Core: In Vitro and In Vivo Evaluations.